03 October 2020 : Clinical Research
Effects and Mechanisms of Dapagliflozin Treatment on Ambulatory Blood Pressure in Diabetic Patients with Hypertension
Zirao Hao1BCDE, Yue Sun1BF, Yingzhen Wen1BF, Lijuan Cui1BF, Guiping Li1DF*, Yan Liu2AGDOI: 10.12659/MSM.925987
Med Sci Monit 2020; 26:e925987
Table 4 Relationship between 24-h ABP and dapagliflozin treatment.
| β | R2 | P | |
|---|---|---|---|
| 24-h SBP | |||
| Unadjusted | −0.58 | 0.37 | <0.001 |
| Adjusted model 1 | −0.29 | 0.25 | 0.02 |
| Adjusted model 2 | −0.12 | 0.14 | 0.10 |
| 24-h DBP | |||
| Unadjusted | −0.14 | 0.10 | 0.18 |
| Adjusted model 1 | −0.06 | 0.05 | 0.34 |
| Adjusted model 2 | −0.02 | 0.02 | 0.63 |
| Daytime SBP | |||
| Unadjusted | −0.62 | 0.41 | <0.001 |
| Adjusted model 1 | −0.33 | 0.32 | 0.009 |
| Adjusted model 2 | −0.20 | 0.19 | 0.06 |
| Daytime DBP | |||
| Unadjusted | −0.16 | 0.11 | 0.12 |
| Adjusted model 1 | −0.09 | 0.05 | 0.23 |
| Adjusted model 2 | −0.03 | 0.02 | 0.40 |
| Nighttime SBP | |||
| Unadjusted | −0.30 | 0.26 | 0.04 |
| Adjusted model 1 | −0.11 | 0.12 | 0.09 |
| Adjusted model 2 | −0.07 | 0.08 | 0.21 |
| Nighttime DBP | |||
| Unadjusted | −0.10 | 0.14 | 0.32 |
| Adjusted model 1 | −0.07 | 0.06 | 0.48 |
| Adjusted model 2 | −0.03 | 0.02 | 0.63 |
| SBP – systolic blood pressure; DBP – diastolic blood pressure. Model 1: adjusted for age, female sex, body mass index, estimated glomerular filtration rate, medication use at follow-up (aspirin, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, calcium channel blocker, beta-blocker, and metformin); and glycated hemoglobin A1c, urine albumin-creatinine ratio and 24-h urine volume at follow-up. Model 2: was additionally adjusted for serum uric acid and 24-h urinary uric acid excretion at follow-up. | |||